Alzheimer's pill targets brain plaques in High-Risk patients
NCT ID NCT04693520
Summary
This study tested whether an oral medication called ALZ-801 could affect biological markers of Alzheimer's disease in people with early symptoms who carry specific genetic risk factors (APOE4 gene). The 84 participants took the pill twice daily for up to four years while researchers measured changes in blood and brain scan markers related to Alzheimer's progression. The main goals were to see if the treatment was safe and whether it affected key Alzheimer's biomarkers like tau protein and brain shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brain Research Center
's-Hertogenbosch, Netherlands
-
Brain Research Center
Amsterdam, Netherlands
-
Brain Research Center
Zwolle, Netherlands
-
Motol University Hospital
Prague, Czechia
-
St. Anne's University Hospital
Brno, Czechia
-
Vestra Clinics
Rychnov nad Kněžnou, Czechia
Conditions
Explore the condition pages connected to this study.